-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PAC-1 in Pancreatic Endocrine Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PAC-1 in Pancreatic Endocrine Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PAC-1 in Pancreatic Endocrine Tumor Drug Details: PAC-1 (also known...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cabozantinib S-malate in Penile Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Penile Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cabozantinib S-malate in Penile Cancer Drug Details: Cabozantinib s-malate (XL184,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ruxolitinib Phosphate in Hypopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ruxolitinib Phosphate in Hypopharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ruxolitinib Phosphate in Hypopharyngeal Cancer Drug Details: Ruxolitinib (INCB18424, Jakafi,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAV-AQP1 in Xerostomia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AAV-AQP1 in Xerostomia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AAV-AQP1 in Xerostomia Drug Details: AAV-AQP1 is under development for the treatment...
-
Product Insights
NewSorrento Therapeutics Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Sorrento Therapeutics Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Sorrento Therapeutics Inc (Sorrento) is a biopharmaceutical company that focuses on developing therapeutics for the treatment of cancer, osteoarthritis and autoimmune diseases. The company’s immunotherapy pipeline portfolio consists of a CD38 CAR-T, CD38 ADC, CD38 DAR-T and Sephrehvir for the treatment of cancer. Sorrento is also investigating COVID19 programs which include Coviguard, Covidrops and Covishield, among others for the...
-
Innovation Ranking
Innovation Ranking – Sorrento Therapeutics Inc
Sorrento Therapeutics Inc (Sorrento) is a biopharmaceutical company that focuses on developing therapeutics for the treatment of cancer, osteoarthritis and autoimmune diseases. The company’s immunotherapy pipeline portfolio consists of a CD38 CAR-T, CD38 ADC, CD38 DAR-T and Sephrehvir for the treatment of cancer. Sorrento is investigating COVID19 programs which include Coviguard, Covidrops and Covishield, among others for the treatment of COVID-19. Its marketed products include ZTlido, a lidocaine topical system for the treatment of postherpetic neuralgia (PHN). The company works...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Etrasimod in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Etrasimod in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Etrasimod in Atopic Dermatitis (Atopic Eczema) Drug Details: Etrasimod...
-
Product Insights
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Drugs In Development, 2023’, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Myocardial Infarction – Drugs In Development, 2023
Global Markets Direct’s, ‘Myocardial Infarction - Drugs In Development, 2023’, provides an overview of the Myocardial Infarction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myocardial Infarction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Hairy Cell Leukemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Hairy Cell Leukemia - Drugs In Development, 2023’, provides an overview of the Hairy Cell Leukemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hairy Cell Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...